Nimodipine Capsules Rx
Generic Name and Formulations:
Nimodipine 30mg; soft-gel caps.
Various generic manufacturers
Indications for Nimodipine Capsules:
To improve neurological outcome of subarachnoid hemorrhage from ruptured intracranial berry aneurysms, regardless of post-ictus neurological condition.
Take on empty stomach. 60mg every 4 hours for 21 consecutive days. Start within 96 hours of subarachnoid hemorrhage. If oral therapy is not feasible, may extract capsule contents into a syringe and give via in situ NG tube, then flush tube with normal saline. Hepatic impairment: 30mg every 4 hours; monitor.
Not for IV or other parenteral administration (may be fatal). Hepatic impairment. Monitor BP, heart rate. Pregnancy (Cat.C). Nursing mothers: not recommended.
May potentiate other calcium channel blockers. Potentiated by cimetidine.
Calcium channel blocker (CCB).
Decreased blood pressure, GI upset, headache, bradycardia, flushing, edema, rash; rare: intestinal pseudo-obstruction and ileus.
Formerly known under the brand name Nimotop.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|